Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, Inc.
Alnylam Appoints Dr. Edward Scolnick to Board of Directors and Scientific Advisory Board
February 29th, 2008
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced the appointment of Edward Scolnick, M.D., to its Board of Directors and Scientific Advisory Board. Dr. Scolnick is the director of the Psychiatry Initiative at the Broad Institute. From 1982 to 2003, Dr. Scolnick served in a number of key leadership roles at Merck Research Laboratories, most recently as president. Prior to joining Merck, he worked at the National Cancer Institute and the National Heart Institute. "We are extremely delighted and honored that Ed has agreed to join the Alnylam board of directors and our scientific advisory board," said John Maraganore, Ph.D., Chief...
Source: Health Business Week (2008-02-29)
|
